Doctors Caution as Ozempic Debuts in India

Novo Nordisk has officially launched Ozempic in India, pricing the 0.25 mg weekly dose at ₹2,200, marking a significant entry into the country’s rapidly growing diabetes and obesity care market. While the drug is already a global bestseller, experts caution that it is not a quick-fix solution and must be paired with disciplined lifestyle changes.

Strict regime essential, say doctors
Health experts highlight that Ozempic, used for both type 2 diabetes management and weight control, requires patients to follow a structured regimen.
“It is a medicine used for both diabetes and weight treatment. While undergoing the course, one should follow a strict regime and engage in regular exercise,” said Dr. Unnikrishnan of Chellaram Diabetes Institute.
He added that the drug supports broader health improvements, including reducing risks related to heart and kidney complications in diabetes patients.

India becomes a key market
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic (semaglutide) in October this year for adult patients with type 2 diabetes. The injectable will be available in 0.25 mg, 0.5 mg, and 1 mg strengths.

With India holding the world’s second-largest type 2 diabetes population and rapidly rising obesity numbers, the country has become a significant market for metabolic and weight-loss medications. Analysts estimate the global segment could reach $150 billion annually by the end of the decade.

Global bestseller with multiple benefits
Ozempic, first approved in the U.S. in 2017, has grown popular worldwide, including for off-label weight-loss use. Novo Nordisk states that beyond glycemic control, the drug can help reduce cardiovascular risks, protect kidney function, and support weight loss of up to 8 kg in diabetes patients.

In India, the medication will be available only on prescription from endocrinologists or internal medicine specialists, and is not approved for cosmetic or non-medical weight loss.